# Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

> **NCT01851330** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 647 (actual)

## Conditions studied

- Chronic Hepatitis C Virus

## Interventions

- **DRUG:** LDV/SOF
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT01851330
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2013-12
- **Final completion:** 2014-03
- **Target enrollment:** 647 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01851330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01851330, "Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01851330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*